我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
38
8 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中(未招募)
4
10.5%
已完成
25
65.8%
Enrolling By Invitation
1
2.6%
尚未招募
3
7.9%
招募中
终止
2
5.3%
暂无批准数据
- Researchers propose the glucose ketone index (GKI), a simple finger-prick blood test measuring the ratio of glucose to β-hydroxybutyrate, as a practical biomarker for tracking metabolic health in non-communicable diseases. - The GKI could help clinicians monitor whether diet, fasting, or exercise interventions shift the body toward nutritional ketosis, a state linked to improved mitochondrial function and potentially lower disease risk. - Non-communicable diseases including cancer, cardiovascular disease, and type 2 diabetes account for roughly three-quarters of deaths worldwide, with mitochondrial dysfunction emerging as a common underlying feature. - The authors call for larger, standardized clinical studies to validate disease-specific GKI target ranges and determine whether the index can reliably predict disease risk, progression, or treatment response.